![Stack of documents and files](/sites/default/files/styles/square_card_l/public/media/images/media-135.jpg.webp?itok=-HVPvHCM)
NICE recommends ibrutinib for relapsed or refractory mantle cell lymphoma
NICE reverses decision on Ibrutinib and recommends it for baseline commissioning in England.
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
NICE reverses decision on Ibrutinib and recommends it for baseline commissioning in England.
Brentuximab vedotin recommended as treatment option for systemic anaplastic large cell lymphoma.
Some people with CLL now able to access venetoclax through Cancer Drugs Fund.